No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
COGT240816C9000
- 0.63
- -0.27-30.00%
15min DelayClose Jul 22 15:59 ET
0.63High0.40Low
0.40Open0.90Pre Close4 Volume150 Open Interest9.00Strike Price223.00Turnover82.60%IV10.82%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.63Extrinsic Value100Contract SizeAmericanOptions Type0.4844Delta0.2133Gamma13.90Leverage Ratio-0.0157Theta0.0024Rho6.74Eff Leverage0.0090Vega
Intraday
- 5D
- Daily
News
Jefferies Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $20
Cogent Biosciences Reaches Alignment With US FDA to Use Patient-Reported Symptom Tracking in Trial
Express News | Cogent Biosciences Inc: Remain on Track to Complete Enrollment in Summit Part 2 in Q2 of 2025 and Report Top-Line Results by Year-End 2025
Express News | Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the Summit Trial
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $19
Express News | Needham Reiterates Buy on Cogent Biosciences, Maintains $18 Price Target
Comments
$Cogent Biosciences(COGT.US$ Reuters· 3 mins ago
Cogent Biosciences Inc: Summit Trial Showed Clinically Meaningful Improvement in Skin Symptoms as Well as Objective Reduction in Skin Lesions
Cogent Biosciences Inc: Summit Trial Showed Clinically Meaningful Improvement in Skin Symptoms as Well as Objective Reduction in Skin Lesions
$Cogent Biosciences(COGT.US$ Cogent Biosciences (COGT) said Thursday that new lead-in data from ongoing phase 3 trial of a combination of bezuclastinib and sunitinib showed potential to become new standard of care for advanced gastrointestinal stromal tumors, a type of cancer.
The company said the combination treatment led to a disease control rate of 80% in all patients and 100% in patients that were previously treated with imatinib only.
"Coupled with the impressive clinical activ...
The company said the combination treatment led to a disease control rate of 80% in all patients and 100% in patients that were previously treated with imatinib only.
"Coupled with the impressive clinical activ...
1
5
$Cogent Biosciences(COGT.US$ Cogent Biosciences Reports Updated Lead-In Data From Ongoing Phase 3 PEAK Trial At ASCO Annual Meeting
Addition of Bezuclastinib to Sunitinib Continues to Be Generally Well-Tolerated With an Encouraging Safety Profile
Addition of Bezuclastinib to Sunitinib Continues to Be Generally Well-Tolerated With an Encouraging Safety Profile
1
Cogent Biosciences Unveils Positive Data from SUMMIT Trial of Bezuclastinib in Nonadvanced Systemic Mastocytosis Patients.
In a significant development for the biotech industry, Cogent Biosciences has announced positive Part 1b data from its SUMMIT trial evaluating Bezuclastinib, a novel targeted therapy, in patients with nonadvanced systemic mastocytosis (SM). The news marks a major milestone in the ongoing efforts to d...
In a significant development for the biotech industry, Cogent Biosciences has announced positive Part 1b data from its SUMMIT trial evaluating Bezuclastinib, a novel targeted therapy, in patients with nonadvanced systemic mastocytosis (SM). The news marks a major milestone in the ongoing efforts to d...
$Cogent Biosciences(COGT.US$ Cogent Biosciences Announces Positive Part 1b Data From SUMMIT Trial Evaluating Bezuclastinib in Patients With Nonadvanced Systemic Mastocytosis
GlobeNewswire· 30 mins ago
GlobeNewswire· 30 mins ago
Read more